Stephen George Dilly, President and CEO at Aimmune Therapeutics, Inc. (AIMT), sold 1,154 shares at $26.24 ($30K) on 2017-10-16, disclosed to the SEC on 2017-10-18.
Scheduled sale ($30k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| SRRA | BUY | 2021-05-20 | $178K | — | Filing → |
| SGMO | SELL | 2020-03-20 | $210K | — | Filing → |
| SGMO | SELL | 2020-03-18 | $90K | — | Filing → |